Electroporation-based DNA immunisation: translation to the clinic

Area of Science:

• Biotechnology
• Immunology
• Vaccinology

Background:

• Plasmid DNA vaccines offer potential against microbial and oncologic diseases.
• Historically, challenges in achieving consistent immunogenicity in large animals and humans have limited DNA vaccine development.
• Effective antigen expression and immune responses are crucial for successful DNA vaccine development.

Purpose of the Study:

• To explore the potential of electroporation (EP) as a delivery method to enhance DNA vaccine efficacy.
• To assess the clinical feasibility of EP-based DNA vaccination.

Main Methods:

• Utilizing electroporation (EP) technology to improve antigen expression from DNA vaccines.
• Developing safe, tolerable, and reproducible EP systems for clinical administration.
• Conducting Phase I clinical trials to evaluate the safety and immunogenicity of EP-based DNA vaccination.

Main Results:

• Electroporation significantly enhances antigen expression and the potency of DNA vaccines.
• EP-based DNA vaccination has advanced to clinical reality with the development of suitable delivery systems.
• Current Phase I trials are investigating the safety and immunogenicity of this approach.

Conclusions:

• Electroporation is a key enabling technology for overcoming the immunogenicity challenges of DNA vaccines.
• EP-based DNA vaccination holds significant promise for clinical applications against various targets.
• The ongoing clinical trials are critical for validating the therapeutic potential of EP-enhanced DNA vaccines.